Redeye: Strax - Low Market Expectations
Redeye lowers its short-term expectations on Strax due to the corona-crisis. Our long-term view of the case remains optimistic, with an experienced team managing the business and a vast distribution network providing a competitive edge. On the back of a solid Q4'19-report and a share price decline of 50% during March, we identify an attractive opportunity for the long-term investor.
Read more and download the research update: https://bit.ly/2Jl3MBf
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/